Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [<sup>18</sup>F]FDG PET/CT in Metastatic Melanomas and Lung Cancer

Immunotherapy with checkpoint inhibitors has prompted a major change not only in cancer treatment but also in medical imaging. In parallel with the implementation of new drugs modulating the immune system, new response criteria have been developed, aiming to overcome clinical drawbacks related to th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Egesta Lopci
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	immunotherapy checkpoint inhibitors metabolic response tumor response [<sup>18</sup>F]FDG PET/CT immuno-PET Medicine R
Acceso en línea:	https://doaj.org/article/a2122bde758c4c94b299e24bfd627065
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a2122bde758c4c94b299e24bfd627065
record_format	dspace
spelling	oai:doaj.org-article:a2122bde758c4c94b299e24bfd6270652021-11-11T17:46:38ZImmunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [<sup>18</sup>F]FDG PET/CT in Metastatic Melanomas and Lung Cancer10.3390/jcm102151602077-0383https://doaj.org/article/a2122bde758c4c94b299e24bfd6270652021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/5160https://doaj.org/toc/2077-0383Immunotherapy with checkpoint inhibitors has prompted a major change not only in cancer treatment but also in medical imaging. In parallel with the implementation of new drugs modulating the immune system, new response criteria have been developed, aiming to overcome clinical drawbacks related to the new, unusual, patterns of response characterizing both solid tumors and lymphoma during the course of immunotherapy. The acknowledgement of pseudo-progression, hyper-progression, immune-dissociated response and so forth, has become mandatory for all imagers dealing with this clinical scenario. A long list of acronyms, i.e., irRC, iRECIST, irRECIST, imRECIST, PECRIT, PERCIMT, imPERCIST, iPERCIST, depicts the enormous effort made by radiology and nuclear medicine physicians in the last decade to optimize imaging parameters for better prediction of clinical benefit in immunotherapy regimens. Quite frequently, a combination of clinical-laboratory data with imaging findings has been tested, proving the ability to stratify patients into various risk groups. The next steps necessarily require a large scale validation of the most robust criteria, as well as the clinical implementation of immune-targeting tracers for immuno-PET or the exploitation of radiomics and artificial intelligence as complementary tools during the course of immunotherapy administration. For the present review article, a summary of PET/CT role for immunotherapy monitoring will be provided. By scrolling into various cancer types and applied response criteria, the reader will obtain necessary information for better understanding the potentials and limitations of the modality in the clinical setting.Egesta LopciMDPI AGarticleimmunotherapycheckpoint inhibitorsmetabolic responsetumor response[<sup>18</sup>F]FDG PET/CTimmuno-PETMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5160, p 5160 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immunotherapy checkpoint inhibitors metabolic response tumor response [<sup>18</sup>F]FDG PET/CT immuno-PET Medicine R
spellingShingle	immunotherapy checkpoint inhibitors metabolic response tumor response [<sup>18</sup>F]FDG PET/CT immuno-PET Medicine R Egesta Lopci Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [<sup>18</sup>F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
description	Immunotherapy with checkpoint inhibitors has prompted a major change not only in cancer treatment but also in medical imaging. In parallel with the implementation of new drugs modulating the immune system, new response criteria have been developed, aiming to overcome clinical drawbacks related to the new, unusual, patterns of response characterizing both solid tumors and lymphoma during the course of immunotherapy. The acknowledgement of pseudo-progression, hyper-progression, immune-dissociated response and so forth, has become mandatory for all imagers dealing with this clinical scenario. A long list of acronyms, i.e., irRC, iRECIST, irRECIST, imRECIST, PECRIT, PERCIMT, imPERCIST, iPERCIST, depicts the enormous effort made by radiology and nuclear medicine physicians in the last decade to optimize imaging parameters for better prediction of clinical benefit in immunotherapy regimens. Quite frequently, a combination of clinical-laboratory data with imaging findings has been tested, proving the ability to stratify patients into various risk groups. The next steps necessarily require a large scale validation of the most robust criteria, as well as the clinical implementation of immune-targeting tracers for immuno-PET or the exploitation of radiomics and artificial intelligence as complementary tools during the course of immunotherapy administration. For the present review article, a summary of PET/CT role for immunotherapy monitoring will be provided. By scrolling into various cancer types and applied response criteria, the reader will obtain necessary information for better understanding the potentials and limitations of the modality in the clinical setting.
format	article
author	Egesta Lopci
author_facet	Egesta Lopci
author_sort	Egesta Lopci
title	Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [<sup>18</sup>F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
title_short	Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [<sup>18</sup>F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
title_full	Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [<sup>18</sup>F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
title_fullStr	Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [<sup>18</sup>F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
title_full_unstemmed	Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [<sup>18</sup>F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
title_sort	immunotherapy monitoring with immune checkpoint inhibitors based on [<sup>18</sup>f]fdg pet/ct in metastatic melanomas and lung cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a2122bde758c4c94b299e24bfd627065
work_keys_str_mv	AT egestalopci immunotherapymonitoringwithimmunecheckpointinhibitorsbasedonsup18supffdgpetctinmetastaticmelanomasandlungcancer
_version_	1718432016731471872

Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [<sup>18</sup>F]FDG PET/CT in Metastatic Melanomas and Lung Cancer

Ejemplares similares